[1]王 超,唐的木,丁 成.司库奇尤单抗联合窄谱UVB照射治疗对中重度斑块型银屑病PASI评分及血 清IgE、IgA、IgG的影响[J].中国美容医学,2024,(8):103-107.
　WANG Chao,TANG Dimu,DING Cheng.Infl uence of Secukinumab Combined with Narrow-band UVB Irradiation on PASI Score and Serum IgE, IgA and IgG in Patients with Moderate-to-severe Plaque Psoriasis[J].Medical Aesthetics and Beauty,2024,(8):103-107.
点击复制

司库奇尤单抗联合窄谱UVB照射治疗对中重度斑块型银屑病PASI评分及血 清IgE、IgA、IgG的影响()
分享到：

《中国美容医学》[ISSN:1008-6445/CN:61-1347/R]

卷:
期数:
2024年8期
页码:
103-107
栏目:
出版日期:
2024-08-10

文章信息/Info

Title:
Infl uence of Secukinumab Combined with Narrow-band UVB Irradiation on PASI Score and Serum IgE, IgA and IgG in Patients with Moderate-to-severe Plaque Psoriasis
文章编号:
1008-6455（2024）08-0103-04
作者:
王 超; 唐的木; 丁 成
(马鞍山市人民医院皮肤科 安徽 马鞍山 243000 )
Author(s):
WANG Chao;  TANG Dimu;  DING Cheng
( Department of Dermatology, Ma’anshan People’s Hospital, Ma’anshan 243000, Anhui, China )
关键词:
斑块型银屑病; 司库奇尤单抗; 窄谱中波紫外线; 免疫球蛋白; 炎症因子
Keywords:
plaque psoriasis;  Secukinumab;  narrow-band UVB;  immunoglobulins;  infl ammatory factors
分类号:
R758.63
文献标志码:
A
摘要:
目的：观察司库奇尤单抗联合窄谱中波紫外线（UVB）照射治疗中重度斑块型银屑病疗效及对患者银屑病面积和严重 程度指数（Psoriasis area and severity index，PASI）评分及血清免疫球蛋白、炎症因子的影响。方法：选取2021年1 月-2023年7月笔者医院皮肤科就诊的80例中重度斑块型银屑病患者，按随机数字表法分为观察组和对照组各40例。对照组予 以窄谱UVB照射治疗，观察组予以司库奇尤单抗联合窄谱UVB照射治疗。两组患者均治疗观察12周，评价临床疗效、治疗前 后PASI及皮肤病生活质量指数（Dermatology life quality index，DLQI）评分；检测患者血清免疫球蛋白（IgE、IgA、 IgG ）及白介素-17（IL-17）、白介素-23（IL-23）、肿瘤坏死因子-α（TNF-α）水平，记录不良反应情况。结果：治疗 后，观察组总有效率95.00%，高于对照组的80.00%（P＜0.05）。治疗后，两组患者PASI、DLQI评分均较治疗前下降，且观 察组PASI、DLQI评分均较对照组低（P＜0.05）。治疗后，两组患者血清IgE、IgA、IgG及IL-17、IL-23、TNF-α水平均较治 疗前下降，且观察组血清IgE、IgA、IgG及IL-17、IL-23、TNF-α水平均较对照组低（P＜0.05）。观察组不良反应总发生 率15.00%，与对照组的7.50%比较差异无统计学意义（P＞0.05）。结论：司库奇尤单抗联合窄谱UVB照射治疗中重度斑块型 银屑病，相较单独窄谱UVB治疗效果更佳，有助于减轻症状、调节免疫功能、抑制炎症水平，对提高患者生活质量有积极意 义，且未明显增加不良反应。
Abstract:
Objective To observe the effi cacy of secukinumab combined with narrow-band ultraviolet B (UVB) irradiation in the treatment of moderate-to-severe plaque psoriasis and its infl uence on Psoriasis Area and Severity Index (PASI) score, serum immunoglobulins, and infl ammatory factors. Methods Eighty patients with moderate-to-severe plaque psoriasis admitted to the Department of Dermatology of the hospital from January 2021 to July 2023 were selected and divided into observation group and control group, with 40 cases in each group according to the random number table method. The control group was treated with narrow-band UVB irradiation, and the observation group received secukinumab combined with narrow-band UVB irradiation. Patients in both groups were treated and observed for 12 weeks. Clinical treatment outcomes, PASI scores, and Dermatology Life Quality Index (DLQI) scores before and after treatment were evaluated. Serum immunoglobulins ( IgE, IgA, IgG), interleukin-17 (IL-17), interleukin-23 (IL-23), and tumor necrosis factor-α (TNF-α) levels were detected, and adverse reactions were recorded. Results After treatment, the total effective rate in the observation group was 95.00%, which was higher than 80.00% in the control group (P＜0.05). PASI and DLQI scores in both groups decreased after treatment compared to before treatment, with the observation group showing lower scores than the control group (P＜0.05). The levels of serum IgE, IgA, IgG, IL-17, IL-23, and TNF-α decreased after treatment in both groups, with lower levels in the observation group compared to the control group (P＜0.05). There was no statistical signifi cance in the total incidence rate of adverse reactions between the observation group (15.00%) and the control group (7.50%) (P＞0.05). Conclusion Secukinumab combined with narrow-band UVB irradiation for the treatment of moderate-to-severe plaque psoriasis has a better therapeutic effect than narrow-band UVB alone. This combination can more eff ectively alleviate symptoms, regulate immune function, and inhibit infl ammation, thereby improving the quality of life for patients without signifi cantly increasing adverse reactions.
更新日期/Last Update: 2024-08-17